Not everyone will already be familiar with “nano-emulsification technology“. But Pressure BioSciences, Inc. (OTCQB: PBIO) has made a revolutionary development with this. The company is now entering the commercial system development era of the production. In addition to this development, final design specifications are currently being finalized, the first build of a patented Ultra Shear Technology™ system will be completed and everything is on track for a commercial launch early next year.
Pressure BioSciences, Inc. is recognized as a leader in the development and marketing of innovative, broadly supportive, pressure-based solutions for a variety of global industries, including the Life Science sector. The products are based on the unique properties of both constant and variable hydrostatic pressure, better known as Pressure Cycling Technology (PCT).
Ultra Shear Technology™ (UST)
In addition to the PCT-platform (more on this later), the company is now proud to present its final design specifications for the commercial production model of its proprietary Ultra Shear Technology™ (UST) based on the nano-emulsification system. The Company has begun construction of the first alpha unit of the commercial model. Once this is realized and approved, Pressure BioSciences will add an additional 15 turnkey systems, meeting the goal of shipping the BaroShear K45 UST system in the first half year of 2021.
What makes the BaroShear K45 important, is that this nano-emulsification system is designed to allow ingredients that are poorly soluble in water to become optically clear. For the water-based biochemistry, it is difficult to access the active ingredients hidden in oil droplets. Poor solubility in water leads to lower absorption and bioavailability of active ingredients. This makes it complicated for manufacturers and researchers to design and deliver the correct dosage of the desired compound. At present, more than 40% of all new chemical compounds are highly insoluble in water. While for potentially new medicines most molecules have to be processed into highly water-soluble solutions.
The UST-platform has been tested for prednisone – a commonly prescribed corticosteroid with systemic anti-inflammatory and immunosuppressive properties. Prednisone is known to be sparingly soluble in water and ethanol. When processed by the UST-platform, prednisone solutions became optically clear and remained stable at room temperature for many weeks. Other nano-emulsions with the same formulation and UST-processing have been shown to be stable at room temperature for a minimum of six months.
Pressure Cycling Technology (PCT)
PCT represents a proprietary technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. The PCT-platform plays a crucial role for tumor analyzes in the new workflow. Data from cancer tissue protein analysis – generated from a new workflow – may lead to improvements in the clinical management of gynecological cancers.
The PCT-systems consist of two major, interdependent components: thepressure cycle instrument and the consumable that contains the cyclic pressure and delivers it to the sample. The PCT-MicroPestle (PCT MP) is the most important and popular consumable item. It facilitates homogenization and precise physical and chemical preparation of very small biological samples. This includes needle biopsies, small suspensions of cells and laser micro-dissected tissue sections. The PCT MP is made of inert fluoropolymer, which provides stability over a wide temperature range and excellent resistance to aggressive chemicals.
Various laboratories have indicated that they are dependent on the unique PCT-systems. The laboratories focus on the development of vaccines and drugs, cancer diagnostics and treatment support. In the days of COVID-19, detecting, preventing and curing infectious diseases has become an even more important research effort.
Pressure BioSciences was awarded a crucial US patent in this quarter for a new high pressure enhanced consumable. The new patent secures and protects the company’s control over its PCT micro device. Earlier, the company announced the grant of another major US patent, “Sample Preparation Devices and Methods“. This new patent brings the intellectual property to a total of 25 patents that are already granted.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.